Radiopharmaceutical · Kills target cells, directed at prostate-specific membrane antigen (PSMA) (FOLH1) · developed by Novartis Pharmaceuticals
AAA817 is a radioligand therapy that binds PSMA on the surface of prostate cancer cells and emits radiation to kill them. It is being studied in PSMA-positive metastatic castration-resistant prostate cancer.
Summary written with AI from the sources listed at the end of this page.
Prostate Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →